<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00769873</url>
  </required_header>
  <id_info>
    <org_study_id>5698</org_study_id>
    <nct_id>NCT00769873</nct_id>
  </id_info>
  <brief_title>Anticoagulation Post Laparoscopic Splenectomy</brief_title>
  <official_title>Effect of Anticoagulation in Reducing the Incidence of Splenic/Portal Vein Thrombosis Post-Laparoscopic Splenectomy Protocol Number: 5698</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Edmonton Civic Employees Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Splenic/portal vein thrombosis is an alarming complication of splenectomy. Retrospective
      studies in the literature have shown the incidence of symptomatic splenic/portal vein
      thrombosis to be between 0.7% (Rattner et al., 1993) to 8% (Winslow et al., 2002). This is a
      single-center, prospective, randomized study in subjects undergoing laparoscopic splenectomy.
      All participants will receive one dose of pre-operative low molecular weight heparin
      (Lovenox®) subcutaneously, 2 hours prior to surgery. Participants will be randomized
      pre-operatively to treatment or control group however the treatment allocation will not be
      revealed until the surgery is complete. Postoperatively, those assigned to the treatment
      group will receive 40 mg of Lovenox® subcutaneously once a day for 21 days; those in the
      control group will not. Patients with severe renal impairment will receive an adjusted dose
      of Lovenox® (30 mg subcutaneous dose daily). All patients will have a baseline abdominal
      Doppler ultrasound preoperatively and a second one done at 14 to 28 days post surgery to
      monitor for the presence of portal vein and/or splenic vein thrombosis. They will also have
      their lipase and liver function tests checked to correlate with the imaging findings.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment was slower than anticipated. Insufficient funding to expand to multi-centered
    trial.
  </why_stopped>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of portal/splenic vein thrombosis post laparoscopic splenectomy</measure>
    <time_frame>three years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Portal Vein Thrombosis</condition>
  <condition>Splenic Vein Thrombosis</condition>
  <arm_group>
    <arm_group_label>Lovenox</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive Lovenox 40mg SC daily (30mg SC daily if creatinine clearance &lt; 30) for 21 days after laparoscopic splenectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Lovenox</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients do NOT receive Lovenox post laparoscopic splenectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>Lovenox 40mg SC daily (30mg SC daily if creatinine clearance &lt; 30) for 21 days</description>
    <arm_group_label>Lovenox</arm_group_label>
    <other_name>Low molecular weight heparin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled to undergo laparoscopic splenectomy at The University of Alberta or Grey
             Nun's Community Hospitals

          -  Capable of understanding the purpose and risks of the study and willing/able to sign a
             statement of informed consent

          -  Willing to undergo daily subcutaneous injections of Lovenox®

        Exclusion Criteria:

          -  Pregnant or nursing

          -  Unable or unwilling to provide informed consent

          -  Bleeding diathesis or currently on anticoagulation therapy (i.e. coumadin, heparin,
             LMWH)

          -  Hemorrhagic cerebral vascular accident

          -  Severe uncontrolled hypertension

          -  Diabetic or hemorrhagic retinopathy

          -  Contradictions to anticoagulation (i.e. active GI bleed, gastric or duodenal ulcer,
             sustained platelet count &lt; 50 x103/uL, splenectomy due to trauma or history of heparin
             induced thrombocytopenia)

          -  Conversion to open splenectomy

          -  Allergy to Lovenox®, heparin, or other low molecular weight heparins

          -  Bacterial endocarditis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Shapiro, MD PhD FRCS(Eng)</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Haili Wang, MD FRCSC</last_name>
    <role>Study Director</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Kopac, MD MSc</last_name>
    <role>Study Director</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grey Nuns Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6L 5X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, Dietrich-Neto F; ENOXACAN II Investigators. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002 Mar 28;346(13):975-80.</citation>
    <PMID>11919306</PMID>
  </reference>
  <reference>
    <citation>Bergqvist D. Low molecular weight heparin for the prevention of venous thromboembolism after abdominal surgery. Br J Surg. 2004 Aug;91(8):965-74. Review.</citation>
    <PMID>15286956</PMID>
  </reference>
  <reference>
    <citation>Chaffanjon PC, Brichon PY, Ranchoup Y, Gressin R, Sotto JJ. Portal vein thrombosis following splenectomy for hematologic disease: prospective study with Doppler color flow imaging. World J Surg. 1998 Oct;22(10):1082-6.</citation>
    <PMID>9747171</PMID>
  </reference>
  <reference>
    <citation>Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br J Surg. 1997 Aug;84(8):1099-103.</citation>
    <PMID>9278651</PMID>
  </reference>
  <reference>
    <citation>Fujita F, Lyass S, Otsuka K, Giordano L, Rosenbaum DL, Khalili TM, Phillips EH. Portal vein thrombosis following splenectomy: identification of risk factors. Am Surg. 2003 Nov;69(11):951-6.</citation>
    <PMID>14627254</PMID>
  </reference>
  <reference>
    <citation>Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep;126(3 Suppl):338S-400S. Review.</citation>
    <PMID>15383478</PMID>
  </reference>
  <reference>
    <citation>Mismetti P, Laporte S, Darmon JY, Buchmüller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg. 2001 Jul;88(7):913-30.</citation>
    <PMID>11442521</PMID>
  </reference>
  <reference>
    <citation>Petit P, Bret PM, Atri M, Hreno A, Casola G, Gianfelice D. Splenic vein thrombosis after splenectomy: frequency and role of imaging. Radiology. 1994 Jan;190(1):65-8.</citation>
    <PMID>8259430</PMID>
  </reference>
  <reference>
    <citation>van't Riet M, Burger JW, van Muiswinkel JM, Kazemier G, Schipperus MR, Bonjer HJ. Diagnosis and treatment of portal vein thrombosis following splenectomy. Br J Surg. 2000 Sep;87(9):1229-33.</citation>
    <PMID>10971433</PMID>
  </reference>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2008</study_first_submitted>
  <study_first_submitted_qc>October 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2008</study_first_posted>
  <last_update_submitted>June 23, 2009</last_update_submitted>
  <last_update_submitted_qc>June 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. James Shapiro</name_title>
    <organization>University of Alberta</organization>
  </responsible_party>
  <keyword>anticoagulation</keyword>
  <keyword>thrombosis</keyword>
  <keyword>portal vein thrombosis</keyword>
  <keyword>splenic vein thrombosis</keyword>
  <keyword>splenectomy</keyword>
  <keyword>randomized</keyword>
  <keyword>laparoscopic splenectomy</keyword>
  <keyword>lovenox</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

